Search global stocks & ETFs...Ctrl K
Learn Mode
OGN
Stock Profile
08-03
Recommended Metric
Score Card
Explore Scores Tab
3.11
Average
Valuation Score
Key Score
4.00
Good
Management
4.00
Good
Growth
5.00
Very Good
Profitability
3.00
Average
Fin. Health
2.00
Bad
Dividends
3.00
Average
Analyst
2.00
Bad
Insider Transactions
Explore Insider Tab ›Buy Transactions
Sell Transactions
Peers
Select stocks to compare
Price Targets & Ratings
View Analysis
1-year price targets, ending May 11, 2027
Current
$13.43
Baseline
High
$14.70
▲
9.46%
Avg
$11.02
▼
-17.97%
Low
$8.08
▼
-39.84%
Analyst Ratings based on 13 Analysts
Strong Buy
000%
Buy
000%
Hold
754%
Sell
538%
Strong Sell
108%
Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company is headquartered in Jersey City, New Jersey and currently employs 10,000 full-time employees. The company went IPO on 2021-05-14. The firm is engaged in developing and delivering health solutions through a portfolio of prescription therapies and medical devices within women's health, biosimilars and a franchise of established medicines across a range of therapeutic areas. The company has a portfolio of approximately 70 medicines and products across a range of therapeutic areas. The company has a portfolio of contraception and fertility brands, including Nexplanon, NuvaRing, and Follistim AQ. Its Biosimilars portfolio spans across immunology and oncology treatments. The company also has a portfolio of established brands, including brands in cardiovascular, dermatology and non-opioid pain management. The company sells these products through various channels, including drug wholesalers and retailers, hospitals, government agencies and managed health care providers, such as pharmacy benefit managers and other institutions.Read More